Air pollution and ST-elevation myocardial infarction treated with primary percutaneous coronary angioplasty: A direct

Marco Zuin1, Gianluca Rigatelli2, Fabio dell'Avvocata2

  • 1Division of Cardiology, Rovigo General Hospital, Rovigo, Italy; Section of Internal and Cardiopulmonary Medicine, Department of Medical Science, University of Ferrara, Ferrara, Italy.

Insights

Higher levels of air pollutants like nitrogen dioxide (NO2), particulate matter (PM10), and ozone (O3) correlate with increased hospital admissions for ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). This study highlights a significant link between daily air quality and acute cardiac events.

Area of Science:

  • Environmental Health
  • Cardiology
  • Public Health

Background:

  • Air pollution is a growing concern for public health.
  • The impact of specific air pollutants on acute cardiovascular events like ST-elevation myocardial infarction (STEMI) requires further investigation.
  • Primary percutaneous coronary intervention (PCI) is a critical treatment for STEMI.

Purpose of the Study:

  • To assess the relationship between daily air pollutant concentrations and hospital admissions for primary PCI in STEMI patients.
  • To investigate the correlation between atmospheric pressure and STEMI admissions.
  • To determine if air pollutant levels exceeding safety thresholds are associated with increased STEMI incidence.

Main Methods:

  • Retrospective analysis of medical and instrumental data from January 2012 to March 2016.
  • Inclusion of patients admitted with STEMI and treated with primary PCI.
  • Collection of daily atmospheric pressure and air pollutant data (NO2, PM10, O3, SO2, CO) from a regional meteorological service.

Main Results:

  • STEMI patients treated with primary PCI were more frequent with atmospheric pressure > 1013.15 hPa (61.8%).
  • High incidences of STEMI admissions occurred when NO2 (83.1%), PM10 (52%), and O3 (8.5%) exceeded safety thresholds.
  • Significant positive correlations were observed between daily STEMI admissions and daily levels of NO2 (r=0.205), PM10 (r=0.349), and O3 (r=0.191).

Conclusions:

  • A direct and significant correlation exists between daily STEMI admissions and daily concentrations of NO2, PM10, and O3.
  • Elevated levels of these air pollutants may contribute to an increased incidence of STEMI requiring primary PCI.
  • Findings underscore the importance of air quality monitoring in cardiovascular health management.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
358
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
353
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
590
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
354
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
368